ConductScience.org, home

Paper20190189

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.

Streetly MJ and 5 others. Blood, 2010. Cited by 102 papers, by iCite.

Cite this record

ConductScience Library. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Papers, record 20190189. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20190189

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.
PubMed
Journal
Blood
PubMed
Year
2010
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
102
iCite
Relative citation ratio, by iCite
2.5
iCite
Revised in PubMed
2021-10-20
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Streetly MJMatthew J
2Maharaj LLenushka
3Joel SSimon
4Schey SASteve A
5Gribben JGJohn G
6Cotter FEFinbarr E

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ApoptosisMajor topic
Cell CycleMajor topic
Galectin 3Major topic
Multiple MyelomaMajor topic
PolysaccharidesMajor topic
Proto-Oncogene Proteins c-bcl-2Major topic
Blotting, Western
Caspases
Cell Proliferation
Coculture Techniques
Enzyme Activation
Humans
Membrane Potential, Mitochondrial
Myeloid Cell Leukemia Sequence 1 Protein
Stromal Cells
Tumor Cells, Cultured

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P01CA081534NIH

Source NIH RePORTER

Download CSV of grants

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111306489The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.Cancer Res2001https://conductscience.org/library/papers/11306489PubMed
218006844Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species.Cancer Res2007https://conductscience.org/library/papers/18006844PubMed
317047062Characterization of the nuclear import pathways of galectin-3.Cancer Res2006https://conductscience.org/library/papers/17047062PubMed
47853416Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin.J Natl Cancer Inst1995https://conductscience.org/library/papers/7853416PubMed
57722446Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo.J Exp Med1995https://conductscience.org/library/papers/7722446PubMed
611872748NF-kappa B as a therapeutic target in multiple myeloma.J Biol Chem2002https://conductscience.org/library/papers/11872748PubMed
79064332Mitochondrial permeability transition is a central coordinating event of apoptosis.J Exp Med1996https://conductscience.org/library/papers/9064332PubMed
811494147The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.Oncogene2001https://conductscience.org/library/papers/11494147PubMed
910602002IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway.Eur J Immunol1999https://conductscience.org/library/papers/10602002PubMed
1012815276Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications.Apoptosis2003https://conductscience.org/library/papers/12815276PubMed
117696855Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions.Glycoconj J1994https://conductscience.org/library/papers/7696855PubMed
128692888Expression of galectin-3 modulates T-cell growth and apoptosis.Proc Natl Acad Sci U S A1996https://conductscience.org/library/papers/8692888PubMed
1311568006Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma.Blood2001https://conductscience.org/library/papers/11568006PubMed
1411023522Insulin-like growth factor I is a dual effector of multiple myeloma cell growth.Blood2000https://conductscience.org/library/papers/11023522PubMed
1512173037Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.Oncogene2002https://conductscience.org/library/papers/12173037PubMed
1615356648PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells.Leukemia2004https://conductscience.org/library/papers/15356648PubMed
1710023775Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.Immunity1999https://conductscience.org/library/papers/10023775PubMed
1811877256Myeloid cell factor-1 is a critical survival factor for multiple myeloma.Blood2002https://conductscience.org/library/papers/11877256PubMed
1915843888On the role of galectin-3 in cancer apoptosis.Apoptosis2005https://conductscience.org/library/papers/15843888PubMed
2011593406Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.Oncogene2001https://conductscience.org/library/papers/11593406PubMed

See all 40 referencesDownload CSV of references

Cited by64

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 102 citations.

PMIDTitleJournalYearIn PapersSource
42363882Engineering Coil-Coiled Domains for the Design of Modular Theranostic Agents: Galectin-3 as a Targeting Moiety.Biomacromolecules2026https://conductscience.org/library/papers/42363882PubMed
42294589Developing Galectin-3-Targeted Therapeutics in Diseases: Three Distinct Galectin-3 Segments for Targeting.Expert Rev Mol Med2026https://conductscience.org/library/papers/42294589PubMed
41557013Drug resistance in chronic myeloid leukemia: the involvement of Galectin-1 and Galectin-3.Mol Biol Rep2026https://conductscience.org/library/papers/41557013PubMed
41080533Galectins-1, -3 and -9 in leukemia: mechanistic insights and therapeutic translation.Front Immunol2025https://conductscience.org/library/papers/41080533PubMed
40566589Galectin-3 Release in the Bone Marrow Microenvironment Promotes Drug Resistance and Relapse in Acute Myeloid Leukemia.Life (Basel)2025https://conductscience.org/library/papers/40566589PubMed
39769262Galectin Plasmatic Levels Reveal a Cluster Associated with Disease Aggressiveness and Kidney Damage in Multiple Myeloma Patients.Int J Mol Sci2024https://conductscience.org/library/papers/39769262PubMed
38946426Glycosylation in the tumor immune response: the bitter side of sweetness.Acta Biochim Biophys Sin (Shanghai)2024https://conductscience.org/library/papers/38946426PubMed
38840921The role of galectins in mediating the adhesion of circulating cells to vascular endothelium.Front Immunol2024https://conductscience.org/library/papers/38840921PubMed
38465210Ginseng-derived type I rhamnogalacturonan polysaccharide binds to galectin-8 and antagonizes its function.J Ginseng Res2024https://conductscience.org/library/papers/38465210PubMed
38455415Galectin inhibitors and nanoparticles as a novel therapeutic strategy for glioblastoma multiforme.Am J Cancer Res2024https://conductscience.org/library/papers/38455415PubMed
37175823Development of Galectin-3 Targeting Drugs for Therapeutic Applications in Various Diseases.Int J Mol Sci2023https://conductscience.org/library/papers/37175823PubMed
36873388Galectin functions in cancer-associated inflammation and thrombosis.Front Cardiovasc Med2023https://conductscience.org/library/papers/36873388PubMed
36814341Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy.Biomark Res2023https://conductscience.org/library/papers/36814341PubMed
36793021Novel fusion protein PK5-RL-Gal-3C inhibits hepatocellular carcinoma via anti-angiogenesis and cytotoxicity.BMC Cancer2023https://conductscience.org/library/papers/36793021PubMed
36759557Targeting galectin-driven regulatory circuits in cancer and fibrosis.Nat Rev Drug Discov2023https://conductscience.org/library/papers/36759557PubMed
36725108The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma.Adv Cancer Res2023https://conductscience.org/library/papers/36725108PubMed
36364232Pectin: A Bioactive Food Polysaccharide with Cancer Preventive Potential.Molecules2022https://conductscience.org/library/papers/36364232PubMed
35582273The bone marrow microenvironment as a mediator of chemoresistance in acute lymphoblastic leukemia.Cancer Drug Resist2019https://conductscience.org/library/papers/35582273PubMed
34572756Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure.Cancers (Basel)2021https://conductscience.org/library/papers/34572756PubMed
34572346Galectins in Cancer and the Microenvironment: Functional Roles, Therapeutic Developments, and Perspectives.Biomedicines2021https://conductscience.org/library/papers/34572346PubMed

See all 64 cited byDownload CSV of cited by

Genes18

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
BAK1578PubTator's text mininghttps://conductscience.org/library/genes/578NCBI Gene
BAX581PubTator's text mininghttps://conductscience.org/library/genes/581NCBI Gene
BBC327113PubTator's text mininghttps://conductscience.org/library/genes/27113NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL2L1598PubTator's text mininghttps://conductscience.org/library/genes/598NCBI Gene
BCL2L1110018PubTator's text mininghttps://conductscience.org/library/genes/10018NCBI Gene
CASP8841PubTator's text mininghttps://conductscience.org/library/genes/841NCBI Gene
CASP9842PubTator's text mininghttps://conductscience.org/library/genes/842NCBI Gene
CCND2894PubTator's text mininghttps://conductscience.org/library/genes/894NCBI Gene
CCNE29134PubTator's text mininghttps://conductscience.org/library/genes/9134NCBI Gene
CDK61021PubTator's text mininghttps://conductscience.org/library/genes/1021NCBI Gene
CDKN1A1026PubTator's text mininghttps://conductscience.org/library/genes/1026NCBI Gene
IGF13479PubTator's text mininghttps://conductscience.org/library/genes/3479NCBI Gene
LGALS33958PubTator's text mininghttps://conductscience.org/library/genes/3958NCBI Gene
NFKBIA4792PubTator's text mininghttps://conductscience.org/library/genes/4792NCBI Gene
PMAIP15366PubTator's text mininghttps://conductscience.org/library/genes/5366NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20190189

GET https://conductscience.org/api/papers/v1/20190189/references?page=2